DelMar Pharmaceuticals, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, agreed to acquire Adgero Biopharmaceuticals, a privately held biopharmaceutical company. Financial terms were not disclosed. "This acquisition is the result of an extensive search for a suitable oncology therapy and provides the combined company with a diversified, late-stage oncology pipeline. During the next 12-18 months, we expect to achieve significant clinical milestones, driven by a seasoned leadership team that will bolster our oncology drug development expertise," Saiid Zarrabian, DelMar President and CEO.